Trial reportScientific reports2024
Safety and efficacy of proactive versus reactive administration of desmopressin in severe symptomatic hyponatremia: a randomized controlled trial.
Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Proactive desmopressin for the prevention of serum sodium overcorrection in moderate-to-severe hyponatremia: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Outcomes with Sodium Overcorrection in Chronic Hyponatremia: A Systematic Review and Meta-analysis.Journal of general internal medicine · 2026Pooled it
- Hyponatremia: Evolving diagnostics and emerging therapeutics in clinical practice.World journal of nephrology · 2026Review
- Hyponatraemic seizure in a healthy adult due to stress-associated non-osmotic vasopressin-mediated antidiuresis on a low-solute background: a case report.International journal of emergency medicine · 2026Article
- Hyponatraemia in heart failure: a mechanistic approach to contemporary management.Heart failure reviews · 2026Review
- Haemostasis and beyond: The expanding role of desmopressin in intensive care.World journal of critical care medicine · 2025Review
- Article
- Plasma Sodium Correction Rates in Patients with Severe Hyponatremia Treated with Hypertonic Saline with and without Proactive Desmopressin.Kidney360 · 2025Article
- Syndrome of Inappropriate Antidiuresis.Journal of the American Society of Nephrology : JASN · 2025Review
- Treatment of hyponatremia: comprehension and best clinical practice.Clinical and experimental nephrology · 2025Review
- Intensive Care Management of Severe Hyponatraemia-An Observational Study.Medicina (Kaunas, Lithuania) · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This randomized controlled trial aimed to evaluate the safety and efficacy of proactive versus reactive desmopressin (DDAVP) strategies in treating severe symptomatic hyponatremia. Conducted from June 20, 2022, to February 20, 2023, it involved 49 patients with serum sodium levels below 125 mmol/L. Patients were assigned to either the proactive group, receiving DDAVP immediately upon diagnosis, or the reactive group, receiving DDAVP only if the serum sodium level tended to be overcorrected. The primary outcome was the incidence of overcorrection. The study revealed no significant difference in the overcorrection incidence between the proactive (16.7%) and reactive (28%) groups (p = 0.54). The change in serum sodium levels at 1, 6, 12, and 24 h were not different, however, at 48 h, the proactive group exhibited a higher but still safe change in serum sodium levels compared to the reactive group (10.3 ± 3.6 mmol/L vs. 7.7 ± 3.6 mmol/L, p = 0.013). Other parameters including time to symptom improvement, total intravenous fluid administered, DDAVP dose, urine volume, hospital stay duration, osmotic demyelination syndrome incidence, and 28-day mortality did not significantly differ between the groups. In conclusion, our findings suggest that there was no significant disparity in overcorrection rates between proactive and reactive DDAVP strategies for treating severe symptomatic hyponatremia. However, further large-scale studies are warranted to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.